• Regulators cleared an XFG-adapted Nuvaxovid formulation for the 2026-2027 COVID-19 vaccination season in the U.S., EU, Japan.
• Sanofi, Takeda hold the approvals under partnership deals, supporting Novavax royalty revenue tied to net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608280830PR_NEWS_USPR_____PH36011) on August 28, 2026, and is solely responsible for the information contained therein.